.jpg)
Global life sciences investor, Novo Holdings, has made a strategic investment in Alentis Therapeutics, a clinical-stage biotechnology company. This move is part of a significant $105 million Series C financing round which aims to accelerate the development of groundbreaking treatments for organ fibrosis and Claudin-1 (CLDN1) positive tumors.
A Significant Investment
The funds from this investment will bolster the clinical development of Alentis Therapeutics' leading investigational therapies, namely ALE.F02 and ALE.C04, as well as the CLDN1 platform development. The Series C funding was led by Jeito Capital, with Novo Holdings and RA Capital Management also participating.
“This funding allows us to aggressively develop CLDN1 biology in oncology and continue with the recruitment of our organ fibrosis trials while advancing our ADC and bi-specific antibodies,” said Dr. Roberto Iacone, CEO at Alentis Therapeutics.
A Strategic Partnership
Novo Holdings brings more than just financial support to the table. Naveed Siddiqi, Senior Partner at Novo Holdings, will be joining the Board of Directors at Alentis Therapeutics. His extensive experience and knowledge in the biotech sector will provide valuable guidance as Alentis continues to develop and expand its therapeutic approach.
Novo Holdings' Track Record
Novo Holdings has a long history of successful investments in high-quality biotechs across Europe and the US. Their Venture Investments team specializes in backing companies that are developing innovative treatments to address unmet medical needs.
“We were encouraged by exciting emerging pre-clinical data in oncology and the potential of CLDN1 targeted therapeutics to treat a wide range of cancers where CLDN1 is highly expressed,” said Siddiqi.
Alentis Therapeutics' Progress
In the past two years, Alentis Therapeutics has made significant advancements. The company is on the verge of completing the ALE.F02 MAD study and has clearly identified the CLDN1+ cancer patient population. It has also established a platform for engineering CLDN1 antibody drug conjugates and bi-specific antibodies.
About Alentis Therapeutics
Founded in 2019, Alentis Therapeutics focuses on developing innovative treatments for CLDN1+ tumors and organ fibrosis. The company's novel approach targets CLDN1, a previously unexploited target that plays a key role in the pathology of tumors and fibrotic disease across multiple organs.
About Novo Holdings
Novo Holdings is a holding and investment company that manages the assets and wealth of the Novo Nordisk Foundation. Its primary goal is to improve people's health and the sustainability of society by generating attractive long-term returns on the assets of the Novo Nordisk Foundation.
Looking Forward
With this new investment, both Alentis Therapeutics and Novo Holdings are poised to make significant strides in the biotech sector. The funding will enable Alentis to continue its important work in the CLDN1 space and generate clinical data from its programs, potentially leading to breakthroughs in the treatment of organ fibrosis and CLDN1+ tumors.
**In conclusion,**
As the biotech sector continues to evolve, strategic investments like this one will be crucial for the development of novel treatments and therapies. With the backing of Novo Holdings, Alentis Therapeutics is poised to pioneer new paths in organ fibrosis and cancer treatment.
Kommentare